MBX Biosciences, Inc. (MBX): Cash & Equivalents
$75.29M
As of 2025-12-31
$54.12M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $75.29M | +52.6% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $49.35M | +61.7% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $30.52M | n/a | 2025-03-17, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| MBX Biosciences, Inc. (MBX) | 2025-12-31 | $75.29M | +52.6% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $110.64M | -65.4% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $111.04M | +55.0% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $90.39M | -10.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $184.84M | +256.4% |
| Erasca, Inc. (ERAS) | 2025-12-31 | $73.81M | +9.0% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $215.46M | +143.3% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $112.28M | +61.5% |
| Harrow, Inc. (HROW) | 2025-12-31 | $72.93M | +54.4% |
Compare MBX, ZBIO, XERS, TRDA side by side · Screen every company in Pharmaceutical Preparations ↗